Virax Biolabs Faces Nasdaq Listing Risk Due to Minimum Bid Price Noncompliance

Virax Biolabs (VRAX) faces a Nasdaq compliance challenge after receiving a notification that the company is not meeting the exchange's minimum bid price requirement. Nasdaq requires listed companies to maintain a minimum bid price of $1 per share. Virax Biolabs must take corrective action to comply with Nasdaq's standards to continue trading on the exchange.

Virax Biolabs Group (NASDAQ: VRAX) has received a notice from Nasdaq indicating that the company is not in compliance with the exchange's minimum bid price requirement. Nasdaq requires listed companies to maintain a minimum bid price of $1 per share. Virax Biolabs has a compliance period of 180 calendar days, or until January 12, 2026, to regain compliance and avoid potential delisting [1].

The company is required to take corrective action to meet Nasdaq's standards and continue trading on the exchange. Nasdaq has given Virax Biolabs a 180-day period to address the compliance issue, which ends on January 12, 2026. Failure to meet this requirement could lead to delisting, which would significantly impact the company's liquidity and market access.

Intelligent Group Limited (INTJ), a company that previously faced a similar situation, successfully regained compliance with Nasdaq's minimum bid price requirement. INTJ received a Nasdaq notice on February 20, 2025, for trading below the $1.00 minimum for 30 consecutive business days. Nasdaq granted an 180-day cure period ending on August 19, 2025. On July 18, 2025, Nasdaq confirmed that INTJ's Class A ordinary shares closed at or above $1.00 for 10 straight trading days, restoring full compliance and closing the deficiency case [2].

While Virax Biolabs has a clear path to compliance, the company must act swiftly to address the issue and avoid any potential negative impact on its stock price and market reputation. Investors should monitor the situation closely and be prepared for any developments that may affect Virax Biolabs' stock performance.

References:
[1] https://seekingalpha.com/news/4469000-virax-biolabs-receives-nasdaq-letter-over-non-compliance-with-minimum-bid-price-rule
[2] https://www.stocktitan.net/sec-filings/INTJ/6-k-intelligent-group-limited-current-report-foreign-issuer-4bb2d29ef875.html